Investigation Of Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Doses Of Vupanorsen In Japanese Healthy Adult Participants With Elevated Triglycerides

NCT ID: NCT04459767

Last Updated: 2020-12-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-08-06
• Study Completion Date: 2020-12-15

Brief Summary

This is a Phase 1, randomized, double blind, third party open (i.e., participant blind, investigator blind and sponsor open), placebo controlled, single ascending dose study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamics of vupanorsen in Japanese healthy adult participants with elevated triglycerides.

Conditions

Healthy

Keywords

Triglycerides

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Vupanorsen 80 milligram (mg)

Participants will receive one, 0.8 milliliter (mL) subcutaneous injection with vupanorsen 100 mg/mL solution

Group Type: EXPERIMENTAL

Vupanorsen

Intervention Type: DRUG

80 mg subcutaneous injection

Vupanorsen 160 mg

Participants will receive two, 0.8 mL subcutaneous injections with vupanorsen 100 mg/mL solution

Group Type: EXPERIMENTAL

Vupanorsen

Intervention Type: DRUG

80 mg subcutaneous injection

Placebo

Participants in Cohort 1 (vupanorsen 80 mg) will receive one 0.8 mL subcutaneous injection with 0.9% sodium chloride in water.

Participants in Cohort 2 (vupanorsen 160 mg) will receive two 0.8 mL subcutaneous injections with 0.9% sodium chloride in water.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subcutaneous injection

Interventions

Vupanorsen

80 mg subcutaneous injection

Intervention Type: DRUG

Placebo

Subcutaneous injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male and female participants must be 20 to 65 years of age, inclusive, at the time of signing the ICD.

2. Participants must have four Japanese grandparents born in Japan.

3. Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests (except for TG levels), and 12 lead ECG monitoring.

4. Fasting TG >= 90 mg/dL at Screening

5. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.

6. BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb)

7. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion Criteria

1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.

2. History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, or HCVAb.

3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

4. History of allergic or anaphylactic reaction.

5. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.

6. Previous administration with an investigational drug within 4 months or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).

7. A positive urine drug test.

8. Screening supine BP >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.

9. Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.

10. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

• AST or ALT level >=1.25 × ULN;
• Total bilirubin level >=1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is=<ULN.

11. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.

12. Blood donation (excluding plasma donations and platelet donations) of approximately 400 mL within 3 months or >=200 mL within a month prior to dosing. Additionally, approximately >=400 mL within 4 months for female participants.

13. History of sensitivity to heparin or heparin induced thrombocytopenia.

14. History of substance abuse within 12 months of the screening visit.

15. Pregnant females; breastfeeding females.

16. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.

17. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

P-one Clinic

Hachioji-shi, Tokyo, Japan

Countries

Japan

References

Fukuhara K, Furihata K, Matsuoka N, Itamura R, Ramos V, Hagi T, Kalluru H, Bramson C, Terra SG, Liu J. A multi-purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo-controlled, single-ascending dose study in adults. Clin Transl Sci. 2023 May;16(5):886-897. doi: 10.1111/cts.13498. Epub 2023 Mar 31.

Reference Type: DERIVED

PMID: 37002654 (View on PubMed)

Related Links

https://pmiform.com/clinical-trial-info-request?StudyID=C4491006

To obtain contact information for a study center near you, click here.

Other Identifiers

C4491006

Identifier Type: -

Identifier Source: org_study_id